References

  1. Jain P, Nijhawan S. Occult hepatitis C virus infection is more common than hepatitis B infection in maintenance hemodialysis patients. World J Gastroenterol. 2008;14(14):2288-9. PubMed | Google Scholar

  2. Knoll GA, Tankersley MR, Lee JY, Julian BA, Curtis JJ. The impact of renal transplantation on survival in hepatitis C-positive end-stage renal disease patients. Am J Kidney Dis .1997;29(4):608-14. PubMed | Google Scholar

  3. Pol S. Hepatitis C virus infection in hemodialyzed patients and kidney allograft recipients. Adv Nephrol. 1995;24:315-30. PubMed | Google Scholar

  4. Chan TM, Lok AS, Cheng IK, Chan RT. A prospective study of hepatitis C virus infection among renal transplant recipients. Gastroenterology. 1993;104(3): 862-8. PubMed | Google Scholar

  5. Donahue JG, Munoz A, Ness PM, Brown DE Jr, Yawn DH, Mac Allister HA Jr et al. The declining risk of post-transfusion hepatitis C virus infection. N Engl J Med. 1992;327(6):369-73. PubMed | Google Scholar

  6. Allander T, Medin C, Jacobson SH, Grillner L, Persson MA. Hepatitis C transmission in a hemodialysis unit: molecular evidence for spread of virus among patients not sharing equipment. J Med Virol. 1994;43(4):415-9. PubMed | Google Scholar

  7. Pereira BJ, Levey AS. Hepatitis C virus infection in dialysis and renal transplantation. Kidney Int. 1997;51(4):981-99. PubMed | Google Scholar

  8. Rigopoulou EI, Stefanidis I, Liaskos C, Zervou EK, Rizos C, Mina P et al. HCV-RNA qualitative assay based on transcription mediated amplification improves the detection of hepatitis C virus infection in patients on hemodialysis: results from five hemodialysis units in central Greece. J Clin Virol. 2005;34(1):81-5. PubMed | Google Scholar

  9. Pol S, Romeo R, Zins B, Driss F, Lebkiri B, Carnot F et al. Hepatitis C virus RNA in anti-HCV positive hemodialyzed patients: significance and therapeutic implications. Kidney Int. 1993;44(5):1097-100. PubMed | Google Scholar

  10. Pol S, Thiers V, Nousbaum JB, Legendre C, Berthelot P, Kreis H et al. The changing relative prevalence of hepatitis C virus genotypes: evidence in hemodialyzed patients and kidney recipients. Gastroenterology. 1995;108(2):581-3. PubMed | Google Scholar

  11. Espinosa M, Martin-Malo A, Alvarez de Lara MA, Aljama P. Risk of death and liver cirrhosis in anti HCV-positive long term haemodialysis patients. Nephrol Dial Transplant.2001;16(8):1669-74. PubMed | Google Scholar

  12. Martin P, Carter D, Fabrizi F, Dixit V, Conrad AJ, Artinian L et al. Histopathological features of hepatitis C in renal transplant candidates. Transplantation. 2000;69(7):1479-84. PubMed | Google Scholar

  13. Periera BJ, Wright TL, Schmid CH, Levey AS. The impact of pretransplantation hepatitis C infection on the outcome of renal transplantation. Transplantation. 1995;60(8):799-805. PubMed | Google Scholar

  14. Jadoul M, Cornu C, Van Ypersele De Strihou C. Universal precautions prevent hepatits C virus transmission: a 54 month follow-up of the Belgian multicenter study. Kidney Int. 1998;53(4):1022-5. PubMed | Google Scholar

  15. Furusyo N, Hayashi J, Kahuda K, Ariyama I, Kanamato-Tanaka Y, Shimiszu C et al. Acute hepatitis C among Japanese hemodialysis patients: a prospective 9-year study. Am J Gastroenterol. 2001;96(5):1592-600. PubMed | Google Scholar

  16. Vallet-Pichard A, Pol S. Prise en charge de l'infection par les virus des hépatites B ou C chez l'insuffisant rénal chronique. EMC-Néphrologie. 2012;9(4): 1-13. PubMed | Google Scholar

  17. Mallet V, Gilgenkrantz H, Serpaggi J, Verkarre V, Vallet-Pichard A, Fontaine H et al. The relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Intern Med. 2008;149(6):399-403. PubMed | Google Scholar

  18. Degos F, Pol S, Chaix ML, Laffitte V, Buffet C, Bernard PH et al. The tolerance and efficacy of interferon-alpha in haemodialysis patients with HCV infection: a multicentre, prospective study. Nephrol Dial Transplant. 2001;16(5):1017-23. PubMed | Google Scholar

  19. Chazouillères O. Recommandations AFEF sur la prise en charge des hépatites virales C. Juin 2015. http://www.afef.asso.fr/rc/org/afef/nws/News/2015/20150527-184857-777/src/nws_fullText/fr/Recommandations%20AFEF%20H%C3%A9patite%20C%20Juin%202015.pdf. Consulté le 15 Octobre 2015.. PubMed | Google Scholar

  20. Carriero D, Fabrizi F, Uriel AJ, Park J, Martin P, Dieterich DT. Treatment of dialysis patients with chronic hepatitis C using pegylated interferon and low-dose ribavirin. Int J Artif Organs. 2008;31(4):295-302. PubMed | Google Scholar

  21. Mousa DH, Abdalla AH, Al-Shoail G, Al-Sulaiman MH, Al-Hawas FA, Al-Khader AA. Alpha-interferon with ribavirin in the treatment of hemodialysis patients with hepatitis C. Transplant Proc. 2004;36(6):1831-4. PubMed | Google Scholar

  22. Van Leusen R, Adang RP, de Vries RA, Cnossen TT, Konings CJ, Schalm SW et al. Pegylated interferon alfa-2a (40 kD) and ribavirin in haemodialysis patients with chronic hepatitis C. Nephrol Dial Transplant. 2008;23(2):721-5. PubMed | Google Scholar

  23. Czul F, Schiff E, Peyton A, Levy C, Hernandez MG, Jeffers L et al. First ribavirin-free Sofosbuvir and Simeprevir treatment of hepatitis C genotype 1 patients with severe renal impairment (GFR < 30 mL/min or dialysis). J Hepatol. 2015;62(Suppl 2):S670-1. PubMed | Google Scholar

  24. Roth D, Nelson A, Bruchfeld A, Liapakis A, Silva M, Monsour H et al. C-surfer: Grazoprevir plus Elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease. J Hepatol. 2015;62 (Suppl 2):S263-4. PubMed | Google Scholar